Who
B. Lynne Parshall
Director
Company insider
Files Form 4 as: Director, Cytokinetics; Director, Foghorn Therapeutics; COO, Ionis Pharmaceuticals; Director, Akcea Therapeutics; Director and 10% owner, Regulus Therapeutics; Director, Cardiodynamics International; Director, Corautus Genetics.
In numbers
- Trades disclosed
- 711
- Buys
- 1
- Sells
- 121
- Bought
- $3.0M
- Sold
- $55.2M
- Companies
- 7
- Companies where not an officer
- 6
- First trade
- 1 Jan 2006
- Last trade
- 1 Sep 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 1 Sep 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $357K5,000 at $71.48 | filing |
| 1 Sep 2026filed 1 Sep 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $357K5,000 at $71.48 | filing |
| 24 Jun 2026filed 25 Jun 2026 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $114K28,000 at $4.08 | filing |
| 24 Jun 2026filed 25 Jun 2026 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $114K28,000 at $4.08 | filing |
| 1 Jun 2026filed 1 Jun 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $370K5,000 at $74.08 | filing |
| 1 Jun 2026filed 1 Jun 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $370K5,000 at $74.08 | filing |
| 27 May 2026filed 27 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —2,851 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,301 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,301 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —2,851 at $0.00 | filing |
| 15 Apr 2026filed 17 Apr 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $340K4,466 at $76.19 | filing |
| 15 Apr 2026filed 17 Apr 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $41K534 at $76.97 | filing |
| 15 Apr 2026filed 17 Apr 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $340K4,466 at $76.19 | filing |
| 15 Apr 2026filed 17 Apr 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $41K534 at $76.97 | filing |
| 2 Mar 2026filed 2 Mar 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $306K5,000 at $61.21 | filing |
| 2 Mar 2026filed 2 Mar 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $306K5,000 at $61.21 | filing |
| 11 Feb 2026filed 13 Feb 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $414K5,000 at $82.72 | filing |
| 11 Feb 2026filed 13 Feb 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $414K5,000 at $82.72 | filing |
| 19 Nov 2025filed 19 Nov 2025 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $324K5,000 at $64.73 | filing |
| 15 Oct 2025filed 16 Oct 2025 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $359K5,000 at $71.74 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 1,357 Shares of StockIONS · dailypolitical.com · 20 Oct 2026Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) vs. Cytokinetics (NASDAQ:CYTK)CYTK · dailypolitical.com · 18 Oct 2026Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)IONS · finanznachrichten.de · 16 Oct 2026Ionis Pharmaceuticals (NASDAQ:IONS) & Upstream Bio (NASDAQ:UPB) Head to Head ReviewIONS · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name B. Lynne Parshall; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.